Topical bevacizumab for corneal neovasculization after penetrating keratoplasty

European Journal of Ophthalmology

Volumn 19, Issue 5, 2009, Pages 870-872

  Saxena, Sandeep ^a   Kishore, Poonam ^a   Pandey, Sukant ^a   Khattri, Mohit ^a   Kumar, Dipak ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

Corneal graft failure; Corneal graft rejection; Corneal neovascularization; Penetrating keratoplasty; Topical bevacizumab

Indexed keywords

BEVACIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CATARACT EXTRACTION; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; GRAFT REJECTION; HUMAN; LENS IMPLANTATION; MALE; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; SLIT LAMP; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CORNEAL NEOVASCULARIZATION; GRAFT REJECTION; HUMANS; KERATOPLASTY, PENETRATING; MALE; MIDDLE AGED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 70549114863     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210901900530     Document Type: Article

References (10)

1. Maguire MG, Stark WJ, Gottsch JD, et al. Risk factors for corneal graft failure and rejection in collaborate corneal transplantation studies: Collaborative Corneal Transplantation Studies Research Group. Ophthalmology 1994; 101: 1536-47.
2. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularised human corneas. Invest Ophthalmol Vis Sci 2000; 41: 2514-22.
3. Cursiefen C, Masli S, Fong T, et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004; 45: 1117-24.
4. Bachmann BO, Bock F, Wiegand SJ, et al. Promotion of graft survival by vascular endothelial growth factor-A neutralization after high-risk corneal transplantation. Arch Ophthalmol 2008; 126: 71-7.
5. Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularisation: Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577-9.
6. Bock F, Onderka J, Dietrich T, et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007; 48: 2545-52.
7. Book F, König Y, Kruse F, Baier M, Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008; 246: 281-4.
8. Gerten G. Bevacizumab (Avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008; 27: 1195-9.
9. Destafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularisation. Arch Ophthalmol 2007; 125: 834-6.
10. Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008; 115: e33-8.